中國醫療集團(08225.HK)啟動抗癡呆臨床研究
中國醫療集團(08225.HK)公布,集團癡呆卒中喜恩防治臨床研究中心與內地頂尖醫療機構啟動抗癡呆臨床萬例真實世界臨床研究。
研究的參加單位有北京大學第六醫院,北京大學第一醫院,解放軍總醫院等國內多家三甲醫院,利用互聯網技術聯動數百家基層醫院,通過臨床研究提高阿爾茨海默病的標準化治療水準。本次啟動的兩個試驗,負責人分別為王華麗及毛之奇,計畫在兩年內完成一萬例病例研究。
集團管理層認為喜恩抗癡呆卒中臨床研究中心參與內地近期70%癡呆領域藥品的上市臨床研究,此次臨床研究和大資料下臨床研究式新藥品推廣會對企業長期收入產生重要影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.